Iron Overload
📧 Sign up to get email alerts when something new happens for Iron Overload.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-12EMA Authorised: Deferasirox Mylan (deferasirox) — Mylan Pharmaceuticals Limited
The EMA has authorised Deferasirox Mylan for iron overload indications, including beta-thalassemia, with Mylan Pharmaceuticals Limited as th…
-
EMA approval · 2026-04-21EMA Authorised: Ferriprox (Deferiprone) — Chiesi Farmaceutici S.p.A.
The European Medicines Agency authorised Ferriprox (deferiprone) from Chiesi Farmaceutici S.p.A. for the treatment of beta-thalassemia and i…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Fully Automated High-Throughput Quantitative MRI of the Liver
This update describes a trial of a fully automated high-throughput quantitative MRI method for liver imaging, with recruitment ongoing in he…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients [Phase 2]
Phase 2 trial evaluating focal iron accumulation in cerebral regions of early amyotrophic lateral sclerosis patients has completed, examinin…
-
EMA approval · 2026-02-05EMA Authorised: Exjade (deferasirox) — Novartis Europharm Limited
The EMA authorised Exjade (deferasirox) by Novartis Europharm Limited for beta-thalassemia and iron overload in the European Union.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.
Clinical trial evaluating quality of life in patients with chronic iron overload due to hemoglobinopathies in Greece, sponsored by Elpen Pha…
-
FDA approval · 2025-12-11FDA Approved: DEFERIPRONE — Original Application (DR. REDDY'S LABORATORIES, INC.)
FDA approved Dr. Reddy's Laboratories' original application for deferiprone, a generic iron chelator, enabling its marketing in the United S…
-
FDA approval · 2025-10-21FDA Approved: DEFERASIROX — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Deferasirox from Actavis Pharma, Inc. This action updates the regulatory status of the product.
-
EMA approval · 2025-09-30EMA Authorised: Deferasirox Accord (deferasirox) — Accord Healthcare S.L.U.
The EMA authorised Deferasirox Accord (deferasirox) for treating iron overload and beta-thalassemia.
-
EMA approval · 2025-09-29EMA Authorised: Deferasirox Mylan (deferasirox) — Mylan Pharmaceuticals Limited
EMA has authorised Deferasirox Mylan (deferasirox) for treatment of iron overload, including in patients with beta-thalassemia. This marks E…
-
FDA approval · 2025-09-08FDA Approved: DEFERASIROX — Original Application (Aurobindo Pharma Limited)
The FDA approved an original ANDA for deferasirox (generic) manufactured by Aurobindo Pharma Limited, expanding access to iron chelation the…
-
FDA approval · 2025-08-15FDA Approved: DEFERIPRONE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Deferiprone submitted by Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
A University of Wisconsin–Madison trial evaluating a confounder-corrected quantitative MRI biomarker of hepatic iron content has completed.
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Ethnic Differences in Iron Absorption (FeGenes)
This clinical trial update notes ethnic differences in iron absorption (FeGenes), sponsored by Cornell University, with conditions including…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.
A clinical trial protocol assesses whether iron overload influences the incidence of liver complications in long-term survivors (≥10 years) …
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
A completed clinical trial evaluating risk factors for liver and pancreas complications and strategies to prevent them in pediatric patients…
-
FDA approval · 2025-05-08FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Deferoxamine Mesylate (Hospira, Inc.), a generic iron chelator.
-
FDA approval · 2025-03-27FDA Approved: DEFERASIROX ORAL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for Deferasirox oral from Ascend Laboratories, LLC, advancing regulatory approval of this iron c…
-
FDA approval · 2025-03-26FDA Approved: FERRIPROX — Supplemental Application (Chiesi USA, Inc.)
The FDA approved a supplemental application for Ferriprox (deferiprone) filed by Chiesi USA, Inc.
-
FDA approval · 2025-03-26FDA Approved: DEFERASIROX — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for Deferasirox submitted by Amneal Pharmaceuticals NY LLC. The supplemental filing updates the …
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients [Phase 2]
An update on the Phase 2 long-term study of CN128 in patients with thalassemia and severe liver iron overload, which has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with Thalassemia [NA]
A completed clinical trial evaluating whether a polyphenol supplement inhibits dietary iron absorption in adults with thalassemia and iron o…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption
A Cornell University-led clinical trial is examining how heme and non-heme iron intake shapes gut microbiota and host iron absorption in ind…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Safety of SP-420 in the Treatment of Transfusional Iron Overload [Phase 1]
Phase 1 trial evaluating safety of SP-420 for transfusional iron overload has been terminated.
-
FDA approval · 2024-11-18FDA Approved: DEFERASIROX — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Deferasirox (Ascend Laboratories, LLC), granting the requested changes under ANDA210519.